300676.SZ SHZ
BGI Genomics Co., Ltd.
1W: +4.7%
1M: +17.9%
3M: +27.9%
YTD: -8.0%
1Y: -12.1%
3Y: -22.2%
5Y: -58.8%
¥45.86 ($6.84)
+1.70 (+3.85%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$96M
-76.6% ▼
5Y CAGR: -15.7%
Capital Expenditures
$529M
+57.2% ▲
5Y CAGR: -3.3%
Free Cash Flow
-$434M
+47.6% ▲
Dividends Paid
$50M
+87.9% ▲
Buybacks
$781M
+0.0% ▲
Net Change in Cash
-$857M
+45.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $2.1B | $1.5B | $809M | $93M | -$912M |
| Depreciation & Amort. | $302M | $371M | $453M | $437M | $484M |
| Stock-Based Comp. | $96M | $0 | $0 | $0 | $0 |
| Change in Working Capital | $956M | $537M | -$1.5B | -$505M | -$189M |
| Other Non-Cash Items | $231M | $91M | $327M | $384M | $713M |
| Operating Cash Flow | $3.6B | $2.5B | $136M | $409M | $96M |
| — Investing Activities — | |||||
| Capital Expenditures | -$301M | -$384M | -$1.3B | -$1.2B | -$529M |
| Acquisitions (Net) | $4M | $6M | $1M | $0 | $0 |
| Investment Purchases | -$3.9B | -$4.2B | -$2.6B | -$4.1B | -$11.8B |
| Investment Sales | $4.4B | $2.3B | $3.2B | $3.3B | $12.1B |
| Other Investing | -$2M | -$20M | $5M | $238M | $562K |
| Investing Cash Flow | $194M | -$2.3B | -$584M | -$1.8B | -$314M |
| — Financing Activities — | |||||
| Net Debt Issuance | $1.3B | -$586M | -$674M | $240M | $155M |
| Stock Repurchased | -$482M | -$26M | -$363M | $0 | -$781M |
| Dividends Paid | -$40M | -$145M | -$143M | -$417M | -$50M |
| Other Financing | $409M | $1.8B | -$81M | -$90M | -$60M |
| Financing Cash Flow | $1.2B | $1.0B | -$1.2B | -$267M | -$683M |
| Net Change in Cash | $4.7B | $1.1B | -$1.4B | -$1.6B | -$857M |
| Cash End of Period | $5.4B | $6.5B | $5.1B | $3.6B | $2.7B |
| Free Cash Flow | $3.3B | $2.1B | -$1.1B | -$828M | -$434M |